Oramed Pharmaceuticals Inc.

Regulatory Filings • Oct 16, 2021

SEC Form 5

Instruction 1(b).

Form 3 Holdings Reported.

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See

FORM 5 UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549 ANNUAL STATEMENT OF CHANGES IN BENEFICIAL

OWNERSHIP

OMB APPROVAL OMB Number: 3235-0362 Estimated average burden

hours per response: 1.0

owned corporation

	Form 4 Transactions Reported.		Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
1. Name and Address of Reporting Person* Friedman Aviad (Last) (First) (Middle) 6 HADASSA ST.			ORMP ] 08/31/2021			[	X Director 10% Owner Officer (give title Other (specify below) below)
(Street) TEL-AVIV (City)	L3 (State)	6451306 (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)					X Form filed by One Reporting Person Form filed by More than One Reporting Person
		or Section 30(h) of the Investment Company Act of 1940 2. Issuer Name and Ticker or Trading Symbol 5. Relationship of Reporting Person(s) to Issuer ORAMED PHARMACEUTICALS INC. (Check all applicable) 3. Statement for Issuer's Fiscal Year Ended (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned 2. Transaction 2A. Deemed 3. 4. Securities Acquired (A) or Disposed 5. Amount of 6. 7. Nature of Date Execution Date, Transaction Of (D) (Instr. 3, 4 and 5) Securities Ownership Indirect (Month/Day/Year) if any Code (Instr. Beneficially Form: Direct Beneficial (Month/Day/Year) 8) Owned at end of (D) or Ownership Issuer's Fiscal Indirect (I) (Instr. 4) (A) or Amount Price Year (Instr. 3 and (Instr. 4) (D) 4) By wholly
1. Title of Security (Instr. 3)

Common Stock 07/04/2021 G(1) 10,000 D \$0 0 D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Common Stock 07/04/2021 G(1) 12,191 D \$0 0 I

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were transferred, for no consideration, to a trust with an independent trustee.

/s/ Aviad Friedman 10/10/2021

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.